Diligence memo · auto-generated · as of July 2, 2026
MorphImmune Inc.
MorphImmune Inc. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
MorphImmune Inc. operates in Other Health Care, based in WEST LAFAYETTE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
MorphImmune Inc. has raised $32M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $17M on 2022-02-04.
Most recent recorded round closed around 2023-05-05.
Valuation (modeled)modeled
Provath models MorphImmune Inc. at approximately $140M (range $35M–$312M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.92× the median modeled value of Series B Other Health Care companies in 2022–2024 (91 peers) — value vs value, same stage and era. Within the normal band (92% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 15 months.
Last raise 3.2 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 1.1× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 89% of Other Health Care peers (5377 compared).
Modeled value ranks above 84% of those peers.
Closest niche peers: Code Biotherapeutics, Inc., Candesant Biomedical, Inc., Artis Holdings, LLC, GIO Blood Ltd, Clarapath, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.